Ocelot Bio is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics designed to significantly improve outcomes for patients with liver disease. The company’s lead clinical candidate, OCE-205, is a therapeutic peptide with a mechanism of action designed to selectively target complications of portal hypertension, such as hepatorenal syndrome with acute kidney injury (HRS-AKI), a serious and life-threatening consequence of end-stage liver disease.
Our passion for improving the lives of people with severe complications of liver disease is the foundation of our company – even our name.
The ocelot is a small wild cat with keen vision and ability to move nimbly and fast. Like the ocelot, we are using our unique abilities to move with purpose and urgency to bring forward novel medical innovations for people with liver disease.
Patients can’t wait and neither will we.